GENELUX-Final-Logo-Notagline.png
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
13 déc. 2024 07h01 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
Katapult_wSM_Color_RGB_web.png
Katapult to Participate in H.C. Wainwright 26th Annual Global Investment Conference
05 sept. 2024 07h00 HE | Katapult Holdings, Inc.
Katapult to participate in investor conference
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
04 sept. 2024 09h15 HE | Cyclacel
Cyclacel to participate at the H.C. Wainwright 26th Annual Global Investment Conference
MonoparTherapeuticsInc..png
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
04 sept. 2024 08h00 HE | Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Full Logo - OKYO .jpg
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
15 août 2024 12h13 HE | OKYO Pharma LTD
LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Crossject participer
Crossject participera à la 26ème Annual Global Investment Conference de H.C. Wainwright
15 juil. 2024 01h30 HE | CROSSJECT
Dijon, France, 15 juillet 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), société pharmaceutique de spécialités en phase avancée de développement réglementaire de ZEPIZURE®,...
Crossject to attend
Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference
15 juil. 2024 01h30 HE | CROSSJECT
Dijon, France, July 15th 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, its emergency...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Participate in Upcoming Investor Conferences
07 mai 2024 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the company’s management will participate in the following investor conferences: Bank of America...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Announces Closing of $4.0 Million Public Offering
13 sept. 2023 16h15 HE | Cingulate Inc.
KANSAS CITY, Kan., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Announces Pricing of $4.0 Million Public Offering
11 sept. 2023 09h22 HE | Cingulate Inc.
KANSAS CITY, Kan., Sept. 11, 2023 (GLOBE NEWSWIRE) --  Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary...